Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Pancreatic Neoplasms 6Prostatic Neoplasms 4Nasopharyngeal Carcinoma 4Carcinoma, Hepatocellular 4Radiation Injuries 3Carcinoma, Non-Small-Cell Lung 3Sarcoma 2Melanoma 2Carcinoma 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thymoma 1Thymic epithelial tumor 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Rectal Neoplasms 1Rare Diseases 1Pancreatic Cancer Non-resectable 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Meningioma 1Locally Advanced Pancreatic Cancer 1Glioma 1Chondrosarcoma 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Heavy Ion Radiotherapy × Clear all
NCT05203250 2025-08-06

Longitudinal Registry Including Patients Treated With Heavy Particles

CNAO National Center of Oncological Hadrontherapy

Recruiting
3,000 enrolled

Neoplasms, Radiation Injuries, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡